Overview

Evaluation of SPN-812 in Preschool-age Children With ADHD

Status:
Not yet recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.
Phase:
Phase 4
Details
Lead Sponsor:
Supernus Pharmaceuticals, Inc.